FeesSafety
Pluang+

AEON Biopharma advances ABP-450 biosimilar to BOTOX®, reports Q3 2026 results, plans Q1 2027 study start

Company Fundamentals
16 Nov 2026, 23:15 WIB
GlobeNewsWire
View Source
Bullish
AEON Biopharma advances ABP-450 biosimilar to BOTOX®, reports Q3 2026 results, plans Q1 2027 study start

AEON Biopharma reported its Q3 2026 financial results and progress on ABP-450, a biosimilar to BOTOX®. The company received FDA feedback supporting its integrated development strategy and submitted an IND for a comparative pharmacodynamic study planned for Q1 2027. AEON expanded molecular similarity evidence to BOTOX® and secured $6.2 million from warrant exercises to fund development. The company aims to build a robust scientific case for ABP-450’s biosimilarity, targeting the $3.5 billion U.S. therapeutic neurotoxin market.

AEON Biopharma's Q3 2026 financial results and corporate update provide context for readers. For those following the health sector, here is Pluang's market snapshot as of Nov 17, 2026 03:31 WIB: out of 150 priced US health stocks, 31 rose and 118 fell today. Notable movers include HRTX at USD 0.29 with a -6.57% change and a typical hold time of 40 days, SLS at USD 7.36 down 6.42% with 96% buy order activity and a 5-day hold time, and ARWR at USD 44.78 down 6.28% with a 17-day hold time.

More News

Disney Q4 outlook strong with 50%+ EPS growth and streaming as key driver

Disney Q4 outlook strong with 50%+ EPS growth and streaming as key driver

Disney's fiscal Q4 report, due November 17, is expected to show strong growth with analysts forecasting over 50% earnings per share (EPS) growth and more than 12% revenue increase. Streaming revenue rose 11% last quarter with margins hitting double d...

Company Fundamentals
Bullish
2 hours ago
Infoblox launches Australia realm on AWS for local DDI management and security.

Infoblox launches Australia realm on AWS for local DDI management and security.

Infoblox has launched a new Australia realm on Amazon Web Services (AWS) in the Sydney region, providing Australian government agencies and enterprises a local option for managing DNS, DHCP, and IP address management (DDI) with enhanced security. Thi...

Market News
Bullish
2 hours ago
European Commission approves RASONQUE for metastatic pancreatic cancer treatment

European Commission approves RASONQUE for metastatic pancreatic cancer treatment

The European Commission has approved RASONQUE (daraxonrasib), the first broad RAS-targeted oral medicine for adults with metastatic pancreatic adenocarcinoma who have had prior systemic therapy. This approval covers patients with or without identifie...

Market News
Bullish
3 hours ago
SPIE acquires Duflex to boost industrial automation and robotics in the Netherlands.

SPIE acquires Duflex to boost industrial automation and robotics in the Netherlands.

SPIE, a European leader in multi-technical services, has acquired Dutch company Duflex B.V. to enhance its industrial automation, machine building, and robotics capabilities. Duflex, with 26 employees and €8 million revenue in 2025, specializes in ta...

Company Fundamentals
Bullish
4 hours ago
Rexel repurchases 3,878 own shares at an average price of €34.67 from Nov 9-13, 2026

Rexel repurchases 3,878 own shares at an average price of €34.67 from Nov 9-13, 2026

Rexel Développement SAS disclosed that it repurchased a total of 3,878 of its own shares between November 9 and November 13, 2026. The average purchase price during this period was approximately €34.67 per share. This buyback is part of an authorized...

Company Fundamentals
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App